Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Anti-CD137
AGEN2373 · 1 trial · 1 indication
DLT in patient in dose escalation phase
According to NCI-CTCAE Version 5.0, vital signs (blood pressure, heartrate, and temperature), physical examinations, 12-lead electrocardiogram, Eastern Cooperative Oncology Group (ECOG) performance status, and clinical laboratory assessments for all dose groups
According to NCI-CTCAE Version 5.0, vital signs (blood pressure, heartrate, and temperature), physical examinations, 12-lead electrocardiogram, Eastern Cooperative Oncology Group (ECOG) performance status, and clinical laboratory assessments for all dose groups
According to NCI-CTCAE Version 5.0, vital signs (blood pressure, heartrate, and temperature), physical examinations, 12-lead electrocardiogram, Eastern Cooperative Oncology Group (ECOG) performance status, and clinical laboratory assessments for all dose groups
| Arm | Type | Description |
|---|---|---|
| 2-Week Monotherapy with AGEN2373 | EXPERIMENTAL | 3+3 Dose escalation of AGEN2373 administered by IV. |
| 3-Week Monotherapy with AGEN2373 | EXPERIMENTAL | 3+3 Dose escalation of AGEN2373 administered by IV. |
| 4-Week Monotherapy with AGEN2373 | EXPERIMENTAL | 3+3 Dose escalation of AGEN2373 administered by IV. |
| Combination Therapy with 3-week AGEN2373 Monotherapy Lead-In Combination with 6-week Botensilimab | EXPERIMENTAL | 3+3+3 Dose escalation of AGEN2373. AGEN2373 and botensilimab administered by IV. |
| Combination Therapy with 3-week AGEN2373 in combination with 6-week Botensilimab | EXPERIMENTAL | 3+3+3 Dose escalation of AGEN2373. AGEN2373 and botensilimab administered by IV. |
| Name | Type | Description |
|---|---|---|
| AGEN2373 | DRUG | An Anti-CD137 Monoclonal Antibody |
| Botensilimab | DRUG | Anti-CTLA-4 Monoclonal Antibody |
Inclusion Criteria: 1. Voluntarily agree to participate by giving signed, dated, and written informed consent prior to any study specific procedures. Participation in pharmacogenomics testing is optional. 2. ≥ 18 years of age. 3. Histologically or cytologically confirmed diagnosis of a solid tumor ...
Top 2 of 4 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| GE Healthcare Technologies Inc. | GEHC | 1 | PHASE1 | GEH200520/GEH200521 |
| Ascentage Pharma Group International Unsponsored ADR | AAPG | 1 | PHASE1 | Olverembatinib |
AGEN2373 is an investigational small molecule therapeutic being developed by Agenus Inc. for the treatment of advanced cancer. It is in Phase 1 clinical development and has been studied in a single completed trial that enrolled 91 patients. It is not approved for any indication.
AGEN2373 is being studied for use in patients with advanced cancer. Its only clinical trial to date, NCT04121676, enrolled 91 adults with advanced cancer in the United States. The trial is completed, and the drug remains investigational rather than approved for routine clinical use.
AGEN2373 is made by Agenus Inc., a biopharmaceutical company that trades under the ticker AGEN. Agenus is the developer responsible for the clinical program evaluating AGEN2373 in advanced cancer.
AGEN2373 is in Phase 1 clinical development. It has completed one Phase 1 trial, NCT04121676, which enrolled 91 patients with advanced cancer. There are currently no active trials listed for AGEN2373, and it is not FDA approved.
AGEN2373 has been evaluated in one clinical trial, NCT04121676, titled Anti-CD137 and Anti-CTLA-4 Monoclonal Antibody in Patients With Advanced Cancer. The Phase 1 trial enrolled 91 adults with advanced cancer in the United States and is now completed.